Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Laboratorios Farmaceuticos Rovi (BME:ROVI) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financial performance over the long term, which in this case looks quite promising. Particularly, we will be paying attention to Laboratorios Farmaceuticos Rovi's ROE today.

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

How Is ROE Calculated?

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Laboratorios Farmaceuticos Rovi is:

24% = €137m ÷ €582m (Based on the trailing twelve months to December 2024).

The 'return' is the profit over the last twelve months. That means that for every €1 worth of shareholders' equity, the company generated €0.24 in profit.

Check out our latest analysis for Laboratorios Farmaceuticos Rovi

What Has ROE Got To Do With Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

A Side By Side comparison of Laboratorios Farmaceuticos Rovi's Earnings Growth And 24% ROE

Firstly, we acknowledge that Laboratorios Farmaceuticos Rovi has a significantly high ROE. Secondly, even when compared to the industry average of 11% the company's ROE is quite impressive. As a result, Laboratorios Farmaceuticos Rovi's exceptional 21% net income growth seen over the past five years, doesn't come as a surprise.

We then compared Laboratorios Farmaceuticos Rovi's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 12% in the same 5-year period.

Earnings growth is an important metric to consider when valuing a stock. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about Laboratorios Farmaceuticos Rovi's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

Is Laboratorios Farmaceuticos Rovi Efficiently Re-investing Its Profits?

The three-year median payout ratio for Laboratorios Farmaceuticos Rovi is 35%, which is moderately low. The company is retaining the remaining 65%. By the looks of it, the dividend is well covered and Laboratorios Farmaceuticos Rovi is reinvesting its profits efficiently as evidenced by its exceptional growth which we discussed above.

Besides, Laboratorios Farmaceuticos Rovi has been paying dividends for at least ten years or more. This shows that the company is committed to sharing profits with its shareholders. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 33%. Therefore, the company's future ROE is also not expected to change by much with analysts predicting an ROE of 25%.

Summary

On the whole, we feel that Laboratorios Farmaceuticos Rovi's performance has been quite good. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.